Medicover AB Class B

Medicover AB Class B

23.35
EUR
-0.15
(-0.64%)
0.57EPS
38.14P/E
3.49BMarket Cap
Feb 10Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 4, 2026

Operator

Welcome to the Medicover Q3 2026 report presentation. For the first part of the conference call, the participants will be in listen-only mode.

During the questions-and-answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now, I will hand the conference over to the speakers, CEO John Stubbington and CFO Anand Patel.

Please go ahead.

John Stubbington

Good morning, everybody. It's John speaking.

Welcome to our Q3 results presentation. It's another consistent quarter where we've seen good growth and it's our seventh quarter of year-on-year margin improvement, which is something that we're really proud of, particularly as it's another challenging sort of comparable quarter from the performance that we had a year ago, so that's pretty good.

Let's just remind everybody that we made a decision to divest our business in India and that was a transaction that was €1.2 billion. You can see that our shareholding of that is 66.1%, which means that approximately we should receive funds of €740 million, which is really, really good, and that we expect that to close sometime in November, which is what we've communicated before, or it will close in Q4.

Medicover and the local partners have sold 100%, so that's a complete exit for us and that means that, in this presentation, that most of the figures, unless stated, are continuing operations. It just tells you that that's the way that we will deal with the communication.

I don't think we should underestimate this achievement. We built a significant presence in India over the period that we were there and we're excited with the funds that we will receive, and that will help us reshape the business for some years to come.

It's exciting times for us. Let's focus back on the quarter: organic growth of 8%, it's a solid performance from us, 2% negative FX impact.

You can see EBIT is up 22%, so that's really good movement for us, a continuing trend that we've established, which, of course, we are very proud of and very happy with. It also comes at a time where we're actually repurposing a lot of our facilities.

If you look back over the course of the last 12 12 months, 118 units we've actually closed. We've been opening units at the same time, but closing a lot of units at the same time.

Of course, as you close units, revenue goes immediately; as you open units, it takes a bit of time for that revenue to build. That's in our mix and will continue to be in our mix for a while.

Healthcare Services revenue was solid and our Sport & Wellness business has a consistent trend, which has carried on throughout the quarter. Diagnostic Services, really good that they're strengthening the fee-for-service revenue.

As we all know, if you have a stronger fee-for-service revenue, you've got more control over pricing. You can see that leverage decreased over the quarter, which is really good for us.

Good revenue, good growth, a very positive movement on our adjusted EBITDA, as you can see, plus 7.1%. Our margin has a pleasing trend, taking us from 17.6 to 17.8%, healthy cash flow and, as I say, leverage down.

If we look at the revenues across the group, if you look at this graph, it's slightly different than normal: on the left-hand side in the light blue, I think, is the whole business; and as we go to the darker blue, we start to look at the continuing business, you can see the difference. We move well in terms of revenue, plus 6%, still healthy growth for us.

As you look at it by country, healthy growth by Poland. We've got a bit of work to do when it comes to Germany and Romania, but we're well aware of that and got plans in place.

Revenue by payer, you can see we strengthen again in the fee-for-service payer, which is very positive for us for the reasons that I explained before. It's also our major payer, which means that people have got a choice of who they use and who they decide to use.

If they're choosing us, that's always a good sign. You can see the governmental income is flat due to all the micro changes that we've talked about before, which we're managing.

It's nice to see, if you look at the funded revenue, that there's a plus 5% there and we're doing a lot of work in that particular sector that is looking quite positive for us. If we look at Healthcare Services, organic growth of 8% with margin expansion, very good indeed.

You can see the revenue up is six 6%, price is approximately 6.3, FX is 1.9. Fee-for-service and other services performed well, which is good.

Sport & Wellness, we've talked about before, has been strong and we continue to open facilities. I think we'll be accelerating that, not only in Q4, but beyond.

Members, Poland grew, Poland had an increase in members. Romania, we talked about last quarter in terms of some of our account management, we're seeing the adjustments that occur there.

Then our ongoing relationships with customers that are either paying us regularly or are part of our loyalty schemes, etc., we're building that consistently. You can see that's 4.1 million people now from 3.6.

Revenue, we've kind of talked about. Revenue by country, Poland healthy.

You can see in the other country, that's mainly due to the repurposing in terms of the property. Romania relates to the membership.

EBITDA margin is very good. You can see 19.1 to 19.8%, very pleased about that and happy for the team.

Got a really strong membership base at 1.5 million. Revenue by payer, you can see each one of them is up, so that's really, really good.

Diagnostic Services, really solid fee-for-service growth, we explained the importance of that earlier in my conversation. Revenue is pleasing and consistent.

You can see quite a bit of that is coming from price and that shows the strength of our fee-for-service, very consistent in terms of building the fee-for-service revenues in this area. Germany, a little bit softer this quarter.

We believe that's a temporary position due to some of the vacation patterns that occurred and some lower activity that should come back. We continue to increase our BDPs, particularly in Poland.

We want to strengthen our position here. Lab tests are up, it's very solid, very very consistent.

You can see the revenue up 6.3%, very steady. Margin, slight change there in terms of the margin.

Again, we think we can manage that over time. Test increase is pretty good.

Revenue by country, it's all up. If you look at the payer mix, it's a much stronger mix and that's a trend that's been happening for quite a period of time, all credit to the team.

That should strengthen our position. We've added one extra slide for you related to some exciting developments that we have with our Genetics team.

We want to give you more detail on our MRD product launch. It's exciting times for them.

Basically, we've got a simple blood test that detects early signs of lung cancer returning. When a patient has their treatment, the traditional method for people to be able to see if anything has happened and have got the clear, of course, is scans and testing.

With this, the blood test can be done a lot earlier and a lot simpler because it doesn't rely on that being tumor tissue for them to be able to search for. It's blood-based, which means that we can do monitoring earlier maybe and actually do it more frequently.

The indications are that that picks up, if there is an issue, 7.4 months earlier. Of course, this is all evidence-based.

It's the methodology we think can transfer to other things, we can expand it. We've actually launched this product now.

We wanted to signpost this literally to really get the word out that we've made this development. We've worked on it for a long period of time.

We've mentioned it before, but we really wanted to get it out there. I'll now hand over to Anand, who will talk through some of the financials in a bit more detail.

Anand, over to you.

Anand Patel

Thank you, John, and good morning, everyone. In summary, I'd say another solid quarter from us with good organic growth and margin accretion year-on-year.

John's mentioned that our total revenues were up 6% with organic revenues of 8%. Bear in mind that's on a continuing basis and John said most of the numbers in the slide are based on a continuing basis.

If you look on a total basis, for a comparator to Q2, our total revenues would be up 8% and our organic revenues would be double-digit. From a profitability perspective, there were good flow through from the revenue numbers into our profits, EBIT in particular, you can see at €49.3 million.

That's a margin rate improvement of 110 basis points year-on-year, which is very good. EBITDAL, which is our cash profit, which we focus on very strongly, you can see there's good growth in terms of year-on-year growth to €70.9 million with rate up 70 basis points year-on-year.

That naturally flows into a stronger EPS of just over €0.16 per share. In terms of healthcare, strong organic revenue growth of 8% with price driving 6%.

Good margin growth across all measures, I'd say, EBITDA is up 70 basis points year-on-year and EBITDAL is up 90 points 90 basis points year-on-year. From a medical cost ratio perspective, it is better in the quarter.

That's kind of masked by a kind of a mix into scaling in our sports businesses, but still the underlying medical cost ratios are strong. In terms of the business unit performances, John's mentioned it, we were strong in sports and ambulatory in Poland, slightly offset by hospitals in Poland and Romania.

In terms of diagnostics, good organic growth again of 8.5%, split roughly 50/50 between price and volume. From an EBITDAL perspective, margins were flat year-on-year at 14.3% and from an EBITDA perspective, margins were marginally down 20 basis points.

That's largely due to softness in Germany and Genetics being offset by stronger performances in Poland, Romania, and the SSU. What we are doing, given the ongoing changes to reform in Q4, is taking action.

We took some action in Q3 and we'll take further actions in Q4 to make sure we're in good shape for the changes in 2027. In terms of other financial metrics, as our EBIT grows and our balance sheet remains broadly stable, our leverage comes down, which is good, down to 2.7.

Our ROIC is up from the start of the year to 14% from 13%. Effective tax rate of 28% for the quarter.

I've mentioned previously, we will be between 26 to 30% for the year, that remains the case. From a cash flow perspective, a bit of a timing issue.

Still strong cash generation, let's be honest, there's strong profits flowing into the business. There's a bit of timing in Q3 from a cash flow perspective.

Some of it is in the base from last year and some of it will kind of revert into Q4. Overall, I think a pretty strong, pretty solid in terms of other metrics.

In terms of usual capex slide, you can see to the left that actually there's still ample headroom between our free cash flow and our investment capex, which is good. On the right, you can see in terms of the percentage spend of revenue, we spent 5.1% of revenues in Q3, largely 50/50 between maintenance and growth.

Two-thirds of it as normal on Healthcare Services and a third on Diagnostics. In terms of capex for the full year, it will still be between 6 to 6.5%, as previously mentioned.

In terms of medical space, broadly unchanged quarter-on-quarter at just over a million square meters. Finally, from a targets perspective, we stand by the targets that we've set before for now.

We've had a strong year, strong seven quarters, as John says. Until there is a call on the closure of the Asian Indian operation, we'll be sticking with these targets.

With that, I'll hand you back to John.

John Stubbington

Thanks, Anand. Key takeaways for us, it's a solid and consistent quarter.

It's got good growth in it, 8% organic growth. The EBIT change up 22% and I think quite an impressive movement from 7.5 to 8.6, I think that's pretty good.

Fee-for-service and Sport & Wellness drove quite a bit of the growth and the acquisitions supported the synergies. The Indian divestment brings us €740 million and we will focus that money on our core countries.

We continue to focus on efficiency. It's really important in healthcare that you generate that constantly.

Make sure that our pricing is appropriate and we've got cost control. I think they're three things we've talked about quite a bit over recent quarters and I think you can see from the fact that we've managed our margins well that that discipline is really in place.

Public reimbursement is a near-term headwind. We've signaled some headwinds that are happening.

We've signaled that before. We've got very much a track record of signaling these things and then manage them out over a short period of time, we fully expect to do the same.

It's exciting times for us. We've got really great opportunities due to the Indian transaction and all the stuff that we're doing on our organic growth.

We're looking forward to future quarters. Finally, as always, a big thank you to all the teams for producing these results.

We really appreciate what you do, particularly our team in Ukraine, who obviously over recent times have had an even tougher time, but still manage to do fantastically well, thank you.

Operator

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad.

The next question comes from Philip Ekengren from Nordea. Please go ahead.

Philip Ekengren

Good morning, John and Anand. Let's start with Germany perhaps.

Is it possible to quantify the margin impact or the potential margin impact from the reimbursement changes to German genetics? How much do you think you realistically can offset during 2027?

Perhaps also, if you could just comment on how large Genetics is of the Diagnostics business? Thank you.

John Stubbington

No problem whatsoever. That's a natural question to ask.

In the way that the reform will come through, it's a little bit vague in terms of the mix of the exact impact on us. It's more of a range, and we'd rather not kind of comment on that at this stage and just go through the first quarter and then give you a much more of a detailed kind of position.

From the modeling that we've done, though, we will see it and we will feel it, but we fully expect to manage it over the course of the next four quarters. As we go through, similar to what happened with the previous reform in Germany, we think we'll be able to handle it in a similar way, which is we'll see it to begin with, and as we go further into the quarters, we should be able to wash it through.

In terms of size, the Genetics, we don't really disclose the exact Genetics position for competitive reasons, but it's obviously not one of the largest businesses that we've got in the group. If it was, then it would be broken out and people would be able to see it.

Philip Ekengren

Makes sense. Thank you.

Then just follow up on Germany perhaps in the quarter. During the call, it sounded quite temporary, but could you just elaborate a bit on what you saw during the quarter and sort of hurting sort of Diagnostics in Germany?

John Stubbington

I think we signaled there about the staffing pattern, different kind of holidays. If you haven't got the doctors there, sometimes you don't get the tests.

You don't get the consultations that occur and it just changes the mix a little bit. It can happen and it frequently happens usually in Q1s and Q3s because you've got the holiday patterns and people decide to take different periods off.

We expect all of that to kind of regulate itself if you take a longer-term position. We'll see as we go through Q4 what actually has happened because, at the end of the day, doctors still need to treat patients to be able to drive their own personal revenues and that, therefore, is reflected in our business, it usually balances out.

Philip Ekengren

Thanks for that. Then perhaps moving on to Healthcare Services.

8% organic growth, some 6% from pricing. What's holding back volume in this quarter and how do you see that progressing into Q4 and into '27?

John Stubbington

This is a reflection of previous quarters rather than the current quarter. If you remember, we've talked quite openly about our pricing position and the fact that the stance we took was price, not volume, yeah, for a period of time, and then we've talked about we do need to change that.

Remember, this is mainly the B2B sector. B2B sectors are not a sector where the decision-making processes happen overnight.

It has a certain cycle to it. We've made the changes we need to make to be able to stimulate our growth.

The two markets that we do this in, which is Poland and Romania, are slightly different sort of start points when we made the changes. As you go through the full cycle of a B2B thing, we should be able to see some of that growth start to come through.

We can see the pipeline or the beginnings of pipeline, we fully expect the B2B to start to move soon.

Philip Ekengren

Thank you, John. I'll get back into the queue.

Thanks.

John Stubbington

No problem. Thanks a lot for the questions.

Operator

The next question comes from Julia Angeleystrand from Handelsbanken. Please go ahead.

Julia Angeli Strand

Hi. Thank you for taking my questions.

My first question is on price contribution and more related to the out-of-pocket payment. What are you seeing there?

Are you seeing a softer dynamic? Perhaps also if you could say what you mean by medium time frame or how far out is that?

John Stubbington

Are you relating to the comments in the statement in terms of how long this will take to wash through? It's slightly different for the different line dependent upon the issue.

If everybody wants context, I'll give the context in one go really, which is that when you look at our revenues, what's impacting us is that you've got three things that are kind of happening at a similar time: you've got the governments each of the countries making different changes, you can see that with the question we just had on Genetics; you've got the fact that we did location changes, got 118 locations disappearing; and then the B2B subject that I've just talked about in terms of the timing and phasing that's related to it. Governmental changes when they change a contract, sometimes that can take a full year before you come out the other end, which is what we just said about Genetics.

Location repurposing, that just washes through. It depends when we started it, depends when we finished, but we've got more openings now that are going to happen than and less closings, we should be in a different cycle.

Then the membership stuff I just talked about. Then all those three then have a slight impact, yeah, that builds up in this circumstance with the fee-for-service.

For us, we signaled before and we actually came through it okay a year ago and we actually came through those quarters okay. We're signaling again because those three things are there and it's appropriate for us to signal.

Then you've got the German Genetics change on top. These will wash through.

These for us are temporary, but they're just with some it's one, two quarters, with some it's three, four.

Julia Angeli Strand

Understand. Then, aside from adapting to the market conditions and adjusting your offering, what would be a good way to utilize your market position in this environment?

Is it a good time to acquire and focus taking market share?

John Stubbington

Oh, I think we're in a really good place. We've got a lot of organic development that's coming through in terms of some of our IT development and some of our consumer-based engagement tools.

When the India transaction closes, as an organization, we should be debt-free. We're facing a world where things look like interest rates are going to go up and the governments are going to be playing with the systems, which could impact some of our competitors in terms of ability to be able to cope with it, and some of the smaller players as well.

We're really well placed to take advantage of some of those dynamics. Whilst we're signaling concerning revenues, our revenues are still strong revenues, yeah?

They're still good revenues. We're signaling, if we sort these problems out, we'll be really well placed.

As a team, we're pretty confident.

Julia Angeli Strand

Okay. Then, just the last one for me and sort of a follow-up to that.

I guess given what you've learned from this quarter and the performance this quarter, is there any area, segment, geography that has given you more confidence in operations?

John Stubbington

Oh, we've got confidence in a lot of our operations. If you run the type of business that we run, which is a portfolio of different companies, you will never have a position where everything is going perfectly, but you'll always have a position where lots of things are going well.

Of course, a lot of it is within the mix. We're feeling confident because we've got lots of things that are going well, that's why our results are good, so that we're very pleased with that.

We have got some challenges, but we've also got a very experienced team that are used to dealing with those challenges and that we face an environment and a circumstance where we've got a lot of choice due to the Indian transaction. We're feeling pretty confident even though that we're signaling some of the short-term issues that we have to manage.

We've got a history of managing these things, but it's appropriate for us to signal it.

Julia Angeli Strand

I guess equally confident across all three core markets, then?

John Stubbington

They've got different challenges. They might be as we go through quarters dreaming ahead that one of them goes stronger, one of them goes weaker for a period of time before we get there.

We've got a history of being able to manage the things that come to us, we'll see where we get to.

Julia Angeli Strand

Okay. Thank you.

John Stubbington

Thanks a lot. Thanks for the questions.

Operator

The next question comes from Jacob Andersson from Danske Bank. Please go ahead.

Jacob Andersson

Good morning, John and Anand. You talked a little bit about this, but could you, perhaps again, what is driving the membership decline in Romania?

Is it just general weaker demand and what are your actions to try to increase members going forward?

John Stubbington

We talked about it last quarter if you remember. We made some decisions ourselves about some of the pricing and we knew that some of the accounts would go for that.

Obviously, there's the economic situation where the organic, the natural growth where businesses are putting on more employees has slowed down a bit. The teams have reworked the product range in terms of finding new niches to be able to stimulate growth.

Romania's a little bit further behind than Poland in some of the changes and stuff to do the stimulation. We expect to see membership growth come back into our business, even though it's a little bit more challenging in terms of some of the economic situation say in Romania.

No, product ranges have been looked at, I think that will help us as we go forward. As I said just earlier, there is a pipeline and that pipeline is visible to the teams and it's stronger than it was, it should come through.

Jacob Andersson

Yeah. Okay.

Appreciate it. Then also what do you believe needs to change for the hospital margins in Poland and Romania to improve and do you expect the pressure to continue into Q4 and the beginning of next year, or how do you view it?

John Stubbington

The hospital situation, it sounds all doom and gloom, but the hospital situation is driven really by the governmental changes, yeah? That affects your revenue mixes.

They don't turn as fast if you have to change your operations, but we are changing our operations if tariffs are changing, if mixes are changing, to be able to accommodate it. Romania does have some blending of governmental contracts with fee-for-service.

Poland doesn't, it's not allowed. You can see that, as a consequence of that, Poland's fee-for-service in hospitals is pretty strong.

It's pockets of issues that we just have to manage. There's elements of our hospitals that are still doing really well and really strong.

Jacob Andersson

Yeah. Okay.

Fair. Just lastly on or within Diagnostics, which areas of advanced testing do you see the strongest growth, and how much can that mix improvement offset the weakness in Germany, would you say, over the coming quarters?

John Stubbington

There's a big trend in all countries related to lifestyle testing. People talk quite often about medical testing that comes from doctors, which is appropriate, but you don't have to do too much research to see I can't say the word, but longevity.

I think I've said it right for once. Longevity just keeps being talked about all the time, and the lifestyle-related tests is testing related to that, you can actually start seeing that in the mix and you definitely see it in the narrative.

That's not necessarily traditional, "I've got a medical problem, I need to get a doctor to give me a test." This can be people wanting to look at different factors.

Example being the strength of my nails, the strength of my hair. That's much more to do with the cosmetic side of life than it is to do with the medical side of life, although there's an element that's related.

There's lots of opportunity when it comes to the Diagnostics side.

Jacob Andersson

Yeah. Okay.

Perfect. No more questions from me.

John Stubbington

Okay.

Operator

The next question comes from Anna Salamon from ABG Sundal Collier. Please go ahead.

Anna Salamon

Thank you, and good morning. I have a few questions.

I'll start off a little bit about India and I'm not sure you can answer questions about capital allocation, but a bit about what the priorities might be for the proceeds of the deal and how short after the close can we expect new targets?

Anand Patel

Obviously, our focus at the moment is concluding the deal. Yep.

We're all focused on doing that in Q4. Post that, management will obviously have a view and we'll have a discussion with our board, and at the appropriate time, we'll give an announcement externally about what we plan to do with the proceeds.

For now, let's just make sure we get the proceeds in. That's all we're focused on.

Anna Salamon

Yeah. Thank you.

Regarding Sport & Wellness, what is the payback time on a new gym and how does a mature gym EBITDA margin look like? How many openings do you have planned for Q2 and Q4 and 2027?

John Stubbington

They are all very interesting questions that you just asked there and they're all questions that our competition would love to know. Yeah.

It's unlikely that I'm going to answer those questions for you, but I feel it's always unfair not to answer a question a little bit. It's obviously a very positive financial impact that we have from that particular side of our business, and if you looked at each question that you asked, it probably goes faster than our core standard healthcare side.

It's accretive for us and it's very positive for us.

Anna Salamon

Thank you. A last question.

The member base fell 4% driven mostly by Romania and weaker hospitals. Do you think this is a trend that might continue or do you expect this to stabilize in the following quarters?

John Stubbington

No, the organic growth from membership is slower and that's an industry thing in both of the markets that we have membership from. That's why we will look to stimulate other products to be able to get more growth coming through, which we've started.

We're well advanced with it. We've got some new products that are in place, we've got some new products that are about to just hit market.

It's also one of the reasons why we develop the sports stuff because that's an alternative membership base that we build. We expect it to go, as we said before, that whilst it has been subdued by price and why there is some market dynamics there that's showing slower growth, I think our competition would actually kill for some of parts of our proposition such as Sport & Wellness that allows us to be a little bit more flexible and dynamic and creative when it comes to product development.

I think we're well placed when it comes to those market dynamics and you should be able to see things come through. Let's see.

Anna Salamon

Perfect. Thank you, John.

John Stubbington

Thank you.

Operator

The next question comes from Kristofer Liljeberg from DNB Carnegie. Please go ahead.

Kristofer Liljeberg

Hi. Good morning.

I have five questions. I hope that's okay.

First one is could you say anything about the return on investments in India, how much you have invested or something like that?

Anand Patel

No. No, we haven't mentioned that.

I think what we have said previously, as is we've invested a disproportionate amount of capital in India over the past few years versus the total base of Medicover, I'd say. I think the other thing I think we shared when we did our last announcement was the last 12 months' profit in India from an EBITDA perspective were about €26 million from memory, and we've secured an enterprise value of €1.2 billion.

I'm not going to give you exact numbers on return on investment, including the amount of equity we've put in, but we put in a fair amount of capital, but it's a very strong return.

Kristofer Liljeberg

Yeah. Okay.

That leads me into my next question. The capex slide you have, was that included or adjusted for India?

Anand Patel

Including. India is about 10% of the business, it will be about 10% of the capex.

Kristofer Liljeberg

Okay. Capex as percentage of sales, I guess that should maybe be lower going forward, excluding India, or?

Anand Patel

Yes. It should be, yeah.

Obviously, as we've been coming to the end of our journey with India, let's call it that, we've been kind of reducing capex in India spend anyway. Look, I've guided full year that we will be between 6 to 6.5% of revenues for total capex on a, let's say, continuing basis, and that's what it will be roughly.

Kristofer Liljeberg

Do you think that's a figure we should expect also for coming years?

Anand Patel

We will guide on coming years at the appropriate time. For now, historically in the last couple of years, we've spent between 5 to 6.5%, so that's not an unreasonable assumption.

We're not guiding on outer years.

Kristofer Liljeberg

Great. Then coming back to Germany and the Genetics business, or of your total Genetics business, how much of that is Germany, and within Germany, if you could give some color maybe on the public funding versus fee-for-service?

John Stubbington

We don't disclose it. I think on the German stuff that we can understand the need to kind of model what will happen with that change, but actually a lot of it will depend upon the mix and a lot of it will depend upon what happens in the market because this change is quite, on face value, is quite brutal.

We'll be able to ride it and come out the other end, but some people won't be able to ride it and come out the other end. I think that we'll see quite a few little micro things that occur.

We're going to sit on this one and just wait until we go through Q4, and then we'll give you more flavor.

Kristofer Liljeberg

Okay. The comments you made here about the reimbursement and near-term pressures, should we see that as a signal that organic growth might be slower here next coming quarters than what we saw in the third quarter?

John Stubbington

We've got decent growth. We might see some slight sort of changes for it, but we've got countermeasures as well.

It's there and it may or may not happen. We'll go through Q4, see where we land, but those pressures are there and that's why we wanted to flag them.

Kristofer Liljeberg

Do you think this will help the next one, two quarters as well, or should we expect more dramatic slowdown and then a pickup in, let's say, three to four quarters from now?

John Stubbington

Dramatic is a big word, yeah? Yeah.

I don't think it's a word that we've used, I wouldn't like to throw that into the mix.

Kristofer Liljeberg

I rephrase it to somewhat instead.

John Stubbington

We're signaling because it could happen. When you have countermeasures, then those countermeasures do come through.

Are they going to all come through on time in Q4 or not? Who knows?

Let's see. We're not sitting here with any particular concern.

We've still got good growth, strong business, strong lines. There's a few things that we've got to manage, I wouldn't overly panic over the signaling, but the signaling should be there because those things are there.

Yeah. Of course, the Genetics thing will hit us.

The Genetics thing will hit us,

Kristofer Liljeberg

yeah. Great.

Then sorry for all my questions. The last one here.

The lack of growth in Romania, would you say that's even mix between hospital market and lower members?

John Stubbington

I think that's fair.

Kristofer Liljeberg

Okay. The lower number of members, is that entirely due to Romania?

Did the number of members grew in Poland, for example?

John Stubbington

They did. I said that earlier in Q3, we had growth in Poland.

It was small growth, we're still cycling out some of that price stuff that we put through. As I said before, I fully expect, as we go through a couple of quarters, you'll see a different picture, but let's see.

Kristofer Liljeberg

Is that a pickup versus previous quarters in Poland?

John Stubbington

I think it is,

Kristofer Liljeberg

yeah. Great.

Thank you.

John Stubbington

It's there in the detail if you want to check it out. Thank you, Kristofer.

Anand Patel

Thanks a lot.

Operator

The next question comes from Mattias Vadsten from SEB. Please go ahead.

Mattias Vadsten

Hi. Thanks for taking my questions.

I'd like to zoom out a bit. The softness that you mentioned in the CEO letter that you've discussed here in the presentation, isn't it really just the Genetics part that obviously comes through here in October 1st?

Isn't that the only thing that is really new here

John Stubbington

versus

Mattias Vadsten

prior communications or?

John Stubbington

Yeah. It's true, yeah.

The three things that I talked about right at the start, where I said government stuff, where I said property and membership, they've been there for a while, yeah. Of course, there's different degrees of different things that are happening, and the Genetics is the new one, yeah.

Of course, when you're talking about three, four things, then there's a mix there that we've got to manage, that we've got to keep an eye on, that's why we've signaled. A lot of these things have been there for a while, our numbers have still been good, we've managed them.

We're signaling because they're still there and there's an extra one, we need to see where we get to Q4, Q1.

Mattias Vadsten

Okay. Sorry to dwell on it, but they have been there and they are not getting worse, I guess?

John Stubbington

Not dramatically worse. Of course, as I've said many times, we're good at managing these things, sometimes you don't see them at all, but they're there.

Mattias Vadsten

Perfect. Thanks, that's very clear.

I just wanted to make sure I had the same question as Kristofer here, I think, on Poland. On the funded business, if you could elaborate as to when this sort of call it weakness or softness first showed with the corporate.

My question was if you saw a pickup here in Q3 and if that's telling us anything about the future, that we are out of the, maybe, the bottom on the

John Stubbington

funded Poland part. Our growth in funded going back in time, if you go back and listen to these calls and look at the data, we've openly said that a big part of that growth came from price.

We've openly said that was related to high inflation and that the high inflation mix is starting to wash out and maybe we kept our prices a little bit too high for a little bit too long and we need to repurpose or make adjustments, which we've done, yeah. As I had said earlier in this call, it's B2B.

It has a sometimes a 9-month cycle, even when you're getting positive signals people are going to buy. It takes a while to come through.

Our pipeline is strong, yeah? You still got a Q4 where there's a bit of a wash-through of some of those issues.

Hopefully, by the time you get to next year, we'll start to see us being a bit stronger in that sector. Let's see what that pattern looks like.

Mattias Vadsten

Thanks. That's very clear.

Then on Romania, I think at its lowest organic revenue growth rate that I can remember, disregarding the lumpiness in COVID, it's always been super strong. My question here is how much of an impact does initiatives with the limitation to greenfield expansion and contract sort of capped at 2025 levels have here?

I think this will remain until 2028, if I'm not mistaken. Please correct me if I'm wrong.

John Stubbington

Can you repeat the question?

Mattias Vadsten

For the hospitals? With the CNAS-contracted beds in Romania.

John Stubbington

Okay. I know what you're talking about now.

Okay.

Mattias Vadsten

If you can elaborate. Is that an important factor or is it rather, yeah, other?

Because I think you can still fill up current hospitals, right, with more?

John Stubbington

Yeah. That particular implication, we should be able to manage, yeah?

We're better placed than some of our competition when it comes to that restriction. We should be able to manage despite that restriction being in place.

There's other things in the mix that are occurring, don't be too obsessed with that particular change from our perspective.

Mattias Vadsten

That's clear. Then sorry for a messy question.

The last one is on the Diagnostic part in Romania, if you could talk about the development here in the quarter and, yeah, the operating environment.

John Stubbington

Yeah. I think the business is good, it's strong.

We're still market leader and we've got growth from the business. Of course, the economic situation that we have is a little bit tougher, and you can kind of see that.

They're a creative team, very experienced team. That's why they're market leaders in their niche down there, and they now will do what we do: repurpose, re-navigate, adjust, and look to compensate.

Mattias Vadsten

Thank you so much.

John Stubbington

No problem. Thanks for the questions.

Operator

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Darius Saftoiu from Jefferies.

Please go ahead.

Darius Saftoiu

Hi, thank you for taking my questions. Just the first one, you said group organic growth including India was still double-digit versus Q3 8% on the continuing business, and you've mentioned some the seasonality impact in Q3 and some temporary headwinds.

Can you discuss a bit about how should we think about the run rate into the continuing business? I appreciate not quantifying, but some of the headwinds and drivers that were different in Q3 than what you expect going forward.

Anand Patel

Yeah. Look, the reason I mentioned the India bit in Q3 was because at the start, John mentioned seven quarters of margin rate accretion, right?

Actually, on a total basis, we've also had seven consecutive quarters of double-digit organic growth, yeah, on a total basis. Now, obviously, we don't expect India to be in the numbers, we hope, from Q1 next year onwards.

Our current run rate for Q3 is 8%. John's mentioned there may be some softening, but we're good at challenging it.

Aside from that, I'm not going to mention anything else in terms of giving guidance on run rates.

Darius Saftoiu

Thank you. Then the second question on Sport & Wellness.

You've mentioned you've opened four new sites in Q3 and 16 this year. You want to expand further, can you talk about a bit about how much white space there is to expand into Poland?

Also, if you can comment a bit on if when you reach your target in Poland, are you considering this strategy in other countries like Romania?

John Stubbington

We're very focused on Poland, so that's where we've decided to execute this particular proposition for very specific reasons. We won't declare the exact numbers that we're going to go for, but you only have to pick up the press in Poland about sport, wellness, gyms that there's a lot of activity of people looking to open facilities.

If you look at any trend, do any research of Western Europe, how many gyms per head of population is there, etc., you'll see that whilst Poland is growing really fast and strong, they're still quite a way behind the rest of Europe, yeah? There's quite a significant space for us to move to.

An increasing trend, of course, with particularly with the younger generation wanting to use this type of facility. We're not at the point where we're thinking that we've hit maturity at all.

Darius Saftoiu

Thank you. My last question, you've mentioned you've closed 118 facilities and opened 140 in the last 12 months.

How should we think about the impact on revenue on this as the new one size take time to ramp? Can you discuss a bit the impact on volume on the drag on organic growth from this change?

Anand Patel

Look, I think in the grand scheme of things, as John mentioned earlier, we have a portfolio of businesses and a portfolio of measures that are going on, which adversely impact the numbers or positively impact the numbers. Look, I'm not going to give you a margin rate increase due to these new sites that we repurpose getting to maturity, but we expect them to step up, right?

We've closed the ones we've closed for the right reasons. We closed them because they were unprofitable.

Or, as we did acquisitions, we were kind of cannibalizing each other's sales. There were sensible financial things to do.

The new ones that we do going forward clearly will be focused on building profitability for our business and will scale over time to hit the return on investment metrics that we set.

Darius Saftoiu

Thank you.

Operator

The next question comes from Bram Buring from Wood. Please go ahead.

Bram Buring

Hi, gentlemen. Sort of a broad question.

There has been a lot of consolidation in the healthcare markets in Poland and Romania. How do you see the opportunities at this point for M&A growth versus organic growth, especially after proceeds from the Indian sale come in?

That's one question.

John Stubbington

We're very excited by it because, obviously, we've got funds available. If you look at the environment that we're in, you've got potential interest rates going up, you've got governments playing with the funds.

We are a very well-placed healthcare organization because you need to look at our payer mix: we have strong fee-for-service payer mix, we have strong funded payer mix, and we do have some governmental pay, which at the moment is being challenged, yeah, but it's not the biggest. If you look at most of the organizations in our markets, it's not that kind of mix.

Most of it is fund-related. Now, if, therefore, the funds are making micro changes, talking about big reforms and, at the same time, interest rates, cost of living is being challenged, then some of the provision network are going to struggle a little bit more with being able to cope with these kind of things.

We, as a group, tend to cope with it well because we're a portfolio. Then when you get hit in one place, another place can help you ride that particular issue for a period of time until you correct yourself.

We think we're extremely well placed at this moment in time, being a soon-to-be debt-free organization with those dynamics happening, and we believe further consolidation will happen. At the same time, since the Indian deal was announced, of course, many people have been knocking on our door.

We're excited and we're looking forward to future quarters and future years.

Bram Buring

Okay. In a nutshell, the weaker environment is creating opportunities for you to take advantage of?

John Stubbington

I believe so.

Bram Buring

Okay. Then, the last question, just a small thing, the FX drag, I'm assuming this is all coming from Romania, unless you say otherwise?

Anand Patel

No, about half of it's from the złoty. The złoty's weakened versus the euro as well, yeah,

Bram Buring

it's

Anand Patel

złoty and the balance is

Bram Buring

leu.

Anand Patel

Predominantly Romania as well, you're right. You're correct on Romania.

Bram Buring

It's both countries are a drag and about equally. Thank you.

Anand Patel

Yeah.

Operator

There are no more phone questions at this time. I hand the conference back to the speakers for any written questions and closing comments.

John Stubbington

First and foremost, thank you, everybody, for those questions. We understand why you're asking them and it's a very interesting time for us, it's good to get those questions and be able to give points of clarity related to the business.

As you can see, we've had a very good quarter, seventh quarter, if you look at it in old co, seventh quarter of double-digit organic growth and year-on-year margin improvement. That consistency is something that we said that we would look to do and it's something that we've definitely delivered.

Congratulations and thank you to all of our teams for the hard work they've put in to be able to deliver that. We're looking forward to the next few quarters and, of course, for what will happen to the shape of our business in the years to come.

It's exciting times for Medicover, watch this space and speak to you all soon. Thank you.